Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00949052 · ClinicalTrials.gov registry record
Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer
A clinical trial, sponsored by Vanderbilt-Ingram Cancer Center.
- Terminated
- Registry status
- 1,000
- Enrollment target
NCT00949052: Clinical Trial study, sponsored by Vanderbilt-Ingram Cancer Center.
NCT00949052 is a clinical trial that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 1,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00949052 was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.
- TERMINATED
- Registry status
- 1,000 participants
- Enrollment target
Study Summary
RATIONALE: Identifying genes that increase a person's susceptibility to second cancers may help the study of cancer treatment. PURPOSE: This study is looking at genetic susceptibility and risk of second cancers in patients who have undergone stem cell transplant for cancer.
Interventions
- OTHER laboratory biomarker analysis
- OTHER medical chart review
- OTHER questionnaire administration
- GENETIC DNA analysis
- GENETIC polymorphism analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2009-01 |
| Est. Completion | 2018-02 |
Why NCT00949052 stopped before completion
NCT00949052 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00949052 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00949052 about?
NCT00949052 is a clinical study titled "Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer". RATIONALE: Identifying genes that increase a person's susceptibility to second cancers may help the study of cancer treatment. PURPOSE: This study is looking at genetic susceptibility and risk of second cancers in patients who have undergone stem cell transplant for cancer.
What is the current status of trial NCT00949052?
This trial is currently terminated. The enrollment target is 1,000 participants. The study started on 2009-01. Estimated completion is 2018-02.
What interventions are being tested in trial NCT00949052?
The interventions under investigation include: laboratory biomarker analysis (OTHER), medical chart review (OTHER), questionnaire administration (OTHER), DNA analysis (GENETIC), polymorphism analysis (GENETIC).
Who is sponsoring clinical trial NCT00949052?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia